SCHEMBL15613531

SCHEMBL15613531

Cc1ncc(COc2cc(F)cc(Oc3ccc(-c4nn(C5CCOCC5)c5ncnc(N)c45)cc3)c2)n1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 10/20 0.51
▸ NUDT14 O95848 1/20 0.51
▸ NUDT5 Q9UKK9 1/20 0.51
▸ LCK P06239 6/20 0.50
▸ LYN P07948 1/20 0.50
▸ SRC P12931 9/20 0.49
▸ KDR P35968 4/20 0.49
▸ TEK Q02763 1/20 0.49
▸ CSK P41240 2/20 0.47
▸ PIK3CD O00329 5/20 0.46
▸ EGFR P00533 5/20 0.46
▸ ABL1 P00519 3/20 0.46
▸ HCK P08631 3/20 0.46
▸ PIK3CA P42336 3/20 0.46
▸ PIK3CB P42338 3/20 0.46
▸ MTOR P42345 3/20 0.46
▸ PIK3CG P48736 3/20 0.46
▸ EPHB4 P54760 3/20 0.46
▸ PRKDC P78527 3/20 0.46
▸ PI4KB Q9UBF8 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613655 0.93 BTK (0.59) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613549 0.88 BTK (0.51) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613599 0.88 BTK (0.46) BTKNUDT14NUDT5LCKLYN
SCHEMBL16886164 0.88 BTK (0.54) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613558 0.87 BTK (0.52) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613671 0.86 BTK (0.51) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613585 0.86 BTK (0.51) BTKNUDT14NUDT5LCKLYN
SCHEMBL16886162 0.86 BTK (0.52) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613652 0.86 BTK (0.54) BTKNUDT14NUDT5LCKLYN
SCHEMBL15613544 0.86 BTK (0.49) BTKNUDT14NUDT5LCKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885NUDT14 2511/4885NUDT5 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback